Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 19Lung Neoplasms 15Multiple Myeloma 13Leukemia, Myeloid, Acute 12Glioma 10Wilms Tumor 9Lymphoma, Non-Hodgkin 9Breast Neoplasms 9Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Osteosarcoma 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Rhabdoid Tumor 7Hepatoblastoma 7Rhabdomyosarcoma 6Ovarian Neoplasms 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Sarcoma, Ewing 5Rectal Neoplasms 5Pancreatic Neoplasms 5Leukemia, Myelomonocytic, Chronic 5

Interventions

Rituximab 88Cyclophosphamide 81Prednisone 48Doxorubicin 44Lenalidomide 37Vincristine 35polatuzumab vedotin 29Magnetic Resonance Spectroscopy 29Gemcitabine 27Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 17tafasitamab 15obinutuzumab 15ibrutinib 14zanubrutinib 13fludarabine phosphate 13pembrolizumab 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × X-Rays × 1 year × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT05359211 2026-03-20

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07098364 2026-01-14

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
33 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

University of Washington

Phase 1/2 Recruiting
35 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡